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• In the pulmonary circulation, the ultimate role 
of liberated adenosine-5'-triphosphate (ATP) is to 
influence vascular tone. 
Extracellular ATP may be derived from sympathetic 
orpurinergic nerves impinging on blood vessels, in 
addition to vascular endothelial cells, erythrocytes, 
thrombocytes and mast cells. Purinergic innervation 
is more marked on the arterial side than the venous, 
and produces vasoconstriction through P2X 
purinoceptors although there is a newly discovered 
non-P^ purinoceptor mediated vasoconstriction 
produced by ATP which remains to be characterized. 
Agonists as well as flow derived shear stress have 
been shown to release ATP from endothelial cells, 
which in turn act on either the same cell in an 
autoregulatory manner, or the ATP may travel short 
distances in the blood to act on endothelial cells 
downstream. Activation of endothelial P2y 
purinoceptors by ATP produces nitric oxide release 
and vasodilation. There are also P2Y purinoceptors 
on pulmonary vascular smooth muscle, and it ap- 
pears that the number ofP2Ypurinoceptors located on 
the smooth muscle is inversely proportional to vessel 
size. 
Unlike other sources of ATP, erythrocytes as well as 
mast cells are relatively mobile and the magnitude oj 
their effect can change due to alterations in their 
number. Thrombocyte derived ATP can be released 
by episodes ofhypoxia,and the P2T purinoceptor on 
thrombocytes may have an autoregulatory function. 
The P2Z purinoceptor is activated by ATP
4
' and has 
been shown to inhibit the activity of natural killer 
cells as well as macrophages inaddition to producing 
degranulation of mast cells.  
It is likely that together with unique features of 
pulmonary vascular smooth muscle, a combination 
of purinoceptor mediated mechanisms contributes to 
the unusual characteristics of the pulmonary circula- 
tion. Such a varied and essential role of purinergic 
regulatory mechanisms in the pulmonary circulation 




.   .  
• When lungs evolved in animals, more primi- 
tive organisms were already using adenosine-5'- 
triphosphate (ATP) as a signal transmitter (1-4). 
Hence it appears that in addition to its intraceflular 
roles in the pulmonary circulation, ATP has sur- 
vived years of evolutionary selection as a<transmit- 
ter, and it has maintained such a role in the lungs. 




eral respects. Almost the entire systemic blood 
volume passes through this fjed, yet it has vascular 
pressure of about 15mmHg, one sixth that of the 
systemic circulation (5,6). It has the largest capillary 
bed in the body, where vessels are exposed to 140 
percent changes in oxygen tension during each car- 
diac cycle, and perhaps the most intriguing charac- 
teristic of the pulmonary circulation is that its ves- 
sels vasoconstrictin response to hypoxia (6,7). These 
adaptations optimize ventilation with regard to per- 
fusion. 
PURINOCEPTORS 
• Based on differential rank orders of agonist 
potency, pharmacologic antagonism, transduction 
mechanism and now cloning, adenosine receptors 
are classified as P15 of which the At, A2 and A3 are 
subtypes, whereas ATP receptors are classified as 
P2 (8-10). P2purinoceptors are subclassified into P^, 
P2Y, P2U (P^), P2T, P  ̂and Pm (Table 1) (10-12). The 
P^ purinoceptor is a ligand gated cation changnel 
(13,14). The P2Y purinoceptors are coupled to G- 
proteins (11), they activate phospholipase C, lead- 
ing to augmented hydrolysis of phosphoinosrtides 
which then produce liberation of intracellular cal- 
cium and activation of protein kinase C (10-12). 
Recombinant P2Ypurinoceptors when expressed in 
Xenopus oocytes and stimulated with agonist, acti- 
vate a Ca
2+
-dependent Cl~ channel producing slow 
oscillatory inward currents, that are characteristic of 
G-protein coupled receptors (15,16). P2Y 
purinoceptors have subtle differences and have been 
further classified into P2Y1, P2Y2 and P2Y3 receptors 
based on pharmacological differences between 
cloned P2Y purinoceptors (10,11) (Fig. 1A). P2Z 
purinoceptors are believed to be activated by 
ATP
4
". They mediate permeabilization of the plas- 
malemma of mast cells and other cells which are 
found in blood (10,17). P2T purinoceptors, for which 
the principal agonist is ADP while ATP is a com- 
petitive antagonist, are found predominantly 
  
Table 1. P  purinoceptor characteristics. 
 
Abbreviations used: IP3 - inositol -1,4,5-triphosphate, DAG - diacylglycerol, UTP - uridine-S'-triphosphate; ATPyS 
- non-hydrolyzable analogue of ATP; a,pmeATP - a,p methylene ATP. 
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P2U          :...............MAADLEPWNSTINGTWEGDELGYKCRFNEDFKYVLLPVSYGVVCVLGLCLNVVALY 
TM2 TM3 
P2Y1          :FVFHMRPWSGISVYMFNLALADFLYVLTLPALIFYYFNKTD............WIFGDVMCKLQRFIFHVN 
P2U :FLCRLKTWNASTTYMFHLAVSDSLYAASLYAASLPLLVYYYARGDHW.PFSTVLCKLVFYTNLY 
TM4 
P2Y1         :LYGSILFLTCISVHRYTGVVH.PLKSLGRLKKKNAVYVSSLVWALVVAVIAPILFYSGTGVRRNK 
P2U :CSILFLTCISVHRCLGVRPLHSLRWGRARYARRVAAVVMVLVLACQAPVLYFVTTSVRGTRFL 
TM5 
P2Y1         :TITCYDTTADEYLRSYFVYSMCTTVFM...........FCIPFIVILGCYGLIVKALI......YKDLDNS....PLRRK 
P2U :RITCHDTSARELFSHFVAYSSVMLGLLFAV.PFSVILVCYVLMA...RRLLKPAYGT..TGGLPRAKRK 
TM6 TM7 





Figure 1. Representation of the amino acid sequence for Pm, P2Yy P^ P2Upurinoceptors. A) Schematic diagram 
comparing the amino acid sequence of Pm, P2y, and P2Y3 receptors, and showing putative membrane spanning 
domains. The shaded circles depict amino acid residues that are conserved between the three receptors. The open 
circles represent non-conserved residues, and the filled circles show residues that are known to be important in the 
function of other Gprotein coupled receptors. Subclassification of the P2Y- G-protein linkedpurinocep tor family into 
Pm, P2Y2 and P2Y3 is based on the following clones: P2Y] (Clone 803; see Ref. 16) and P2Y2 (Clone P2R; see Ref. 15). 
Another recombinant brain derived receptor (see Ref. 11) when expressed, responds to agonists with yet another 
activity series and has a strong preference for ADP. Northern hybridization revealed the presence ofmRNAfor this 
receptor in the brain and in several peripheral tissues. It has been designated P2Y3. B) The amino acid sequence for 
P2Y1 and P2Upurinoceptors derivedfrom cDNA and aligned for maximum homology. The chicken Pm purinoceptors 
has362aminoacid^(seeRef.7),andthemouseP2Upurinoceptorhas373aminoacids(seeRef.25).Thelikelystartpositions 
of the transmembrane helices, as deduced from hydropathy plots, are shown by the symbols TMl to TM7. 
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on platelets and their megakaryocyte progenitors 
(18,19). P2U purinoceptors are also coupled to phos- 
pholipase C via G-proteins (20,21), but unlike P2Y 
purinoceptors they are activated by UTP as well as 
ATP (22,23). There is a high degree of sequence 
homology between P2Y1 and P2U purinoceptors (Fig. 
IB). Other subclassess of P2 purinoceptors have 
been proposed, such as P3, P,^, and P^ (24-27), for 
which clearly delineated differences have not yet 
been shown. The Pi;2N subtype may be synonymous 
with P2U purinoceptors (10,12), and it may be best to 
consider them as a subclass of P2Y purinoceptors due 
to their coupling with G-proteins. 
PURINERGIC MECHANISMS OF THE 
PULMONARY CIRCULATION 
• Pulmonary vascular smooth muscles possess 
K
+
 channels which are directly inhibited by hypoxia, 
producing depolarization and consequently vaso- 
donstriction (28-30). Other factors can contribute to 
the increase ,i«/y,asGular pressure produced by .hy- 
poxia through additional vasoconstriction or with- 
drawal of vasadilation. Perivascular nerves, endo- 
thelial cells and blood born cells are the three major 
sources from which ATP may be released in the 
mammalian lung. ATP has a vasodilator effect via 
P2Y purinoceptjors (31-33) of a type similar to P2Y2 
(15), or via P^ purinoceptors, a vasoconstrictor 
effect (31, 33-35). In other va'scular beds, sensory 
neurons are known to release ATP and in this way 
produce vasomotor effects (4),.,although to date 
there has not been any such report with regard to the 
pulmonary circulation. A combination of mecha- 
nisms, including purinergic, provide the basis for the 
jinufual physiology of the pulmonary circulation, 
the focus of this review will be on mechanisms 
whetf ATP is the transmitter... acting on P2 
purinDGeptors. 
PURINERGIC VASOCONSTRICTION 
     Periy;ascular nerves which release ATP 
 
In the pulmonary circulation, there,is a large varia- 
tion in the distribution and density of innervation 
dependanton.species (5,36) as well as development 
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tal stage (6,37). The adrenergic system is under- 
stood with considerable depth (5,38,39), whereas 
appreciation of the purinergic system is more recent 
(40). Although ATP can potentially be released 
from sympathetic nerves as a cotransmitter along 
with noradrenaline and neuropeptide Y, to date 
visualization of non-sympathetic-purinergic inner- 
vation to pulmonary vessels has not been reported. 
There are quinacrine sensitive paratracheal neurones 
(Belai and Burnstock, personal communication) 
which need to be studied more closely to establish 
their identity and potential function. Quinacrine is a 
fluorescent acridine dye, which binds nucleotides 
with some selectivity for ATP, and can be used to 
label cells where ATP is concentrated (41-43). 
Quinacrine, sometimes in combination with strate- 
gic neurotoxins, has been successfully used in non- 
pulmonary tissues where purinergic innervation is 
known to exist (44,45). 
      Vasoconstriction by P2X purinoceptors 
With [
3
H] a,p-meATP as a high affinity ligand for 
autoradiographic localization of P  ̂ purinoceptors, 
togetherwithnon-radiolabelledpurinoceptorligands, 
in cat as well as in human tissue, was found that all 
vessels in the pulmonary circulation could be la- 
belled (46). However, both medium and small-sized 
arteries had a higher density of specific binding sites 
than the large elastic arteries or veins. It was con- 
cluded that both P ând P2Y purinoceptors are present 
in small intrapulmonary arteries and that the 
purinergic innervation is more marked on the arte- 
rial side than the venous. In the rat, investigation 
with intracellular recording from small 
intrapulmonary arteries of 100-200 |im external 
diameter revealed an excitatory junctional potential 
which was resistant to sympathectomy (40) pro- 
duced by either guanethidine, 6-hydroxydopa-mine 
or reserpine (47). Using a,p-meATP, the potent and 
slowly degradable P  ̂ purinoceptor agonist (48) to 
desensitize P  ̂ purinoceptors, Inoue and Kannan 
(40) showed that the magnitude of excitatory junc- 
tional potentials produced by electrical stimulation 
cbuld be significantly attenuated without changing 
the membrane potential by the desensitization pro- 
cedure. Furthermore, the membrane depolarization 
induced by ATP was significantly reduced, but not 
14 Hass6ssian 
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completely inhibited by a,p-meATP produced de- 
sensitization, while the depolarization induced by 
noradrenaline or serotonin was not affected (40). 
Such studies are supported by others using isolated 
vessels and the vascular bed, which showed that 
pulmonary vessels of various species contain P^ 
purinoceptors which produce vasoconstriction when 
stimulated (33,34,49). 
In some tissues, the P^ purinoceptor is coupled to 
prostaglandin synthesis (10,51,52). Furthermore, it 
is known that ATP is sequentially brocken down to 
adenosine by ectoenzymes (53-55). In this regard it 
was shown that ATP produces vasoconstriction in 
the pulmonary vascular circulation in part by a direct 
effect and in part indirectly following metabolism of 
ATPto adenosine (34). An A^'llke" receptor coupled 
to a phospholipase is activated by adenosine,, to 
produce the release of thromboxane A2. The direct 
effect of ATP through the ?„, purinoceptor is not 
coupled to a phospholipase (34). Observations such 
as these prompted examination of the role of P^ 
purinoceptors in the vasoconstriction evoked by 
acute hypoxia (50). Desensitization of the PM 
purinoceptor with repeated application of a,P~ 
meATP blocked vasoconstriction in response to p,"y 
-meATP, a P^ purinoceptor selective agonist, but 
did not affect the vasoconstriction in response to 
hypoxia (50).  
•        A novel vasoconstrictor mechanism 
In the presence of 100 |iM NG-nitro-L-arginine- 
methyl-ester (L-NAME) and under basal tone, the 
vasoconstriction evoked by ATP injected into the 
Krebs perfusate of the rat pulmonary circulation 
does not change following desensitization of P,^ 
purinoceptors with a,p-meATP (Fig. 2) (35). Since 
desensitization of P^ purinoceptors on isolated pul- 




.  .                                                                                  2 min 
Figure 2. Polygraph traces showing responses of the pulmonary vascular pressure topurinergic agonists. 
A) The response to 1.0 /jmoleATP and 0.001 jjtnole cc,fi-meATP before desensitization ofP^purinoceptors. 
The P^purinoceptor was desensitized using multiple injections of a, fl-meATP without shifting the basal 
vascular pressure. B) Following P^purinoceptor desensitization ATP is still capable of evoking vasocon- 
striction, demonstrating the presence of vasoconstrictor P2purinoceptors in addition to those of the P^ 
subtype. 
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significantly reduces ATP evoked depolarization 
(40), the above described observation may indicate 
that ATP, injected into the vascular lumen, produces 
the release of a vasoconstrictor from endothelium. 
Another possibility is that exogenous ATP is stimu- 
lating P_rpurinoceptors on vascular smooth muscle. 
Hence, there exist at least two exciting possibilities 
which need to be verified before the source of this 
newly discovered vasoconstriction can be estab- 
lished. 
This ATP evoked vasoconstriction through the non- 
P^ purinoceptor mechanism is not sensitive to 
indomcthacin, although in this preparation the vaso- 
constriction evoked by adenosine or a,p-meATP is1 
attenuated after inhibition of prostaglandin synthe- 
sis (35). Furthermore, glibenclamide will attenuate 
PJX purinoceptor mediated vasoconsiriction in [lie 
rat pulmonary circulation but not that mediated by 
the non-P^, purinoceptor mechanism. The location, 
cellular mechanism, and role of these non-P,v 
purinoceptors which are activated by ATP remains 
to be established. Hence, there exists in the rat 
pulmonary circulation two ATP mediated vasocon- 
strictor mechanisms that can be distinguished from 
each other in at least three ways. These exciting new 
observations put purine nucleotides back into con- 
tention as a mediator of hypoxic pulmonary vaso- 
constriction. 
•       Integrator role of the innervation 
Well over half of the total pulmonary vascular 
resistance lies in vessels under neural control (5, 
56). thus ATPreleased from perivascular nerves can 
participate in the control of a sizeable portion of the 
pulmonary circulation. In this respect, it was shown 
that hypoxic stimulation of the carotid and aortic 
chemoreceptors reflexly decreased the compliance 
of ihe large pulmonary arteries over the entire vas- 
cular bed (57,58). 
However, alveolar hypoxia increases predominantly 
the resistance of intrapulmonary arteries (7,57), and 
vasoconstriction in response to hypoxia is resistant 
to sympathectomy (59-61). There is still much to be 
learned regarding the physiological implications of 
pulmonary blood vessel innervation (5) and thus the 
role of ATP released from perivascular nerves. 
Whether or not nerve mediated regulation enhances 
alveolar-capillary gas exchange by redirecting pul- 
monary blood flow is entirely speculative (7,57,62), 
a more likely function of the neuronal input is to 
maintain a proper balance between the resistance 
and compliance characteristics of the pulmonary 
circulation to ensure comportment between the out- 
put of the right and left ventricles (5,63). 
PURIHERG1C VASODILATOR MECHANISMS 
      Releasable ATP of endothelium 
Endothelial cells play an important role as the 
inactivator of circulating vasoactive substances, and 
ectoenzymes on their plasma membrane are respon- 
sible for the degradation of purincs (8,53-55). Ad- 
enosine is taken up by an active mechanism and 
subsequently synthesized into ATP (64,65). Vaso- 
active agents are differentially released in response 
to various stimuli and in this way play a major role 
in the local modulation of the circulation (56,66). 
Furthermore, endothelialcells arehcterogenous with 
regard to their content of relcasable vasoactive 
agents as well as their cell surface receptors (66-69), 
and this may explain the characteristic reaction to 
various stimuli of different vascular beds. 
2       Liberation of ATP from endothelial cells 
Various stimuli have been demonstrated to release 
ATP from endothelial cells (66.70,71). The release 
of vasoactive substances from endothelial cells is 
likely to involve K* efflux and Ca2+ influx in addition 
to the liberation of Ca.2+ from intracellular stores by 
inositol-l,4,5-triphosphate (72-74). As with other 
non-excitable cells, endothelial cells do not have 
voltage dependent Ca24" channels (74,76). The efflux 
of K~ will hyperpolarize the cell and thus increase 
the driving force for Ca2* entry. In addition to agonist 
evoked ATP release from endothelial cells (75, 
Bodin and Burnstock. personal communication), we 
found that increased flow derived shear stress will 
also evoke release of ATP in the pulmonary circula- 
tion (76). Pulmonary vascular flow increases as 
much as 100 fold during the cardiac cycle (37), 
therefore, ATP is constantly being released by in-   
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creases in flow which occur during each systole 
(74). We have found ihatsuramin, the P2purinoceptor 
antagonist (77-79), will raise pulmonary vascular 
pressure under condition of increasing flow and 
flow derived shear stress (78). The ATP release in 
response to increased flow could be blocked by 
glibenclamidc (76), a blacker of intracellular ATP 
sensitive K+ channels (80) although the ability of 
glibenclamidc to block Ca:+ regulated K~ channels 
has also been demonstrated (81.82). We concluded 
that flow evoked ATP release would also be func- 
tional under hypoxic condition (76). where shear 
stress would increase due to vasoconstriction 
(7,83,84). The ATP that released from pulmonary 
cndothelial cells could either act on the same endot- 
helial cell in an autoregulatory mechanism, or travel 
short distances in the blood to act on endothelial P,y 
purinoceptors downstream in an autocrine manner 
(56, 66, 85). 
       pH related effects on ATP release 
During hypoxic conditions, lactic may be released to 
the extracellular space (86), and ATP liberation (87, 
88), as well as the nitric oxide released by ATP. is 
dependent on a rise in [Ca2+]. which in part is due to 
Ca2+ influx (75,89). Although there is evidence that 
Ca2+ binding to cell membranes is pH dependent 
(90,91). and alkalinixation of extracellular- buffer 
enhances agonist-induced Ca2" influx in bovine aor- 
tic endothelial cells (92-94). how, if at all. variations 
in pH affect endothelium in relation to purinergic 
mechanism is an important question which has not 
yet been addressed. 
•        Vasodilation evoked by endotlielial ATP 
There is evidence for a vasodilator function of ATP 
which is released from endothelial cells in response 
to increased flow (Fig. 3). Furthermore, endothelial 
ATP may function to counter vasoconstriction dur- 
ing hypoxia. In some species, the vasodilau'on evoked 
by P .purinoceptors is endothelium dependent (31). 
and blocked by inhibition of nitric oxide synthesis 
with L-NAME (33), demonstrating that activation 
of pulmonary endothelial P2Y purinoceptors by ATP 
evoked release of nitric oxide. 
Endothelial P . purinoceptors are coupled to a phos- 
pholipase   C by a GPT-binding protein such that 
activation of the P2Y purinoceptor induces a rapid 
and transient rise of inositol-1.4,5-triphosphate in 
endothelial cells (84.95,96). In the pulmonary circu- 
lation, the vasodilator effect of P2Y purinoceptor 
stimulation is not dependent on the release of va- 
sodilator prostaglandins (32,97). Similarly, the va- 
sodilation effect of ATP in the pulmonary vascular 
bed is not mediated by adenosine (32,98). 
       Endothelium  independent vasodilation 
After confirming that endothelium was removed by 
showing the absence of a vasodilator response to 
acetylcholine, Liu and colleagues (31) found a 
persistanl vasodulaiion by human small pulmonary 
arteries in response to ATP. Such a vasodilation was 
also produced by non-hydrolyzablc analogues of 
ATP, therefore degradation of ATP to adenosine 
and A, purinoceptor mediated vasodilation could be 
excluded. The same group has found P,Y 
purinoceptors to be on endothelium of only large (2- 
4mm) human pulmonary arteries (49,99). and they 
have concluded that P2Y purinoceptor localization 
differs between big and small pulmonary arteries 
such that the number of P2Y purinoceptors located on 
the smooth muscle are inversely proportional to the 
size of the vessel. From these studies it is logical to 
postulate that the big arterioles which have a large 
number of P2Y purinoceptors on their endothelial 
surfaces would show a more marked effect on 
endothelial cell damage than the small arterioles. 
B Regulation of vascular tone by endothe- 
lium 
More and more it is becoming clear that vascular 
smooth muscle is situated between two opposing 
regulators. A vasoconstrictor innervation adjusts 
vascular tone relative 10 ihe perfusion requirement 
of the whole animal, and a vasodilator endolhelium 
adjusts vascular tone relative lo Ihe local milieu 
(100,101). Following endothelium cell damage. P^ 
purinoceplor derived vasoconstriction could pro- 
duce vasospasms, and if the endothelial cell damage 
is more extensive hypertension may ensue (6). In 
view of this, the smooth muscle P,Y purinoceptors 
have particular importance in the therapeutic use of 
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Figure 3. A schematic diagram representing the purinergic components of the vasoactive mechanisms in t/ie 
pu!monar\
:
 circulation discussed in the texi. Stimuli acting on purinergic nerves, endolhelial cells, mast cells or 
erythrocytes will produce the release of ATP. Depicted are the P^.P.^pu rinoceptors of vascular smooth muscle, and 
the P .Ypurinoceptors ofendotlielial cel/s. Also shown are the mobile thrombocytes and mast cells with respectively 
P^purinocepforsandP purinoceptors. Tlievasoconstrictor P.purinoceptorsrhat are active even after a, fi-meATP 
produced desensiiization are not placed since Their location remains to be established. 
  
purines for pulmonary vasodilation. 
PURIMERGIC MECHANISMS OF 
BLOOD BORN CELLS 
•       Constituents of blood which release ATP 
In addilion lo neurons and endolhelial cells of the 
pulmonary circulation, erylhrocytes and mast cells 
release ATP in response to various stimuli (5.102- 
107). Unlike other sources of ATP. these cells are 
relatively mobile and the magnitude of their effect 
can change due to alterations in their number (Fig. 
3}. Thus an increase in heamatocrit following chronic 
alveolai1 hypoxia (6,108) would alter purine medi- 







• Vasoactive ATP released from erythro- 
cytes and thrombocytes 
Kivity and Soutirada (107) reported that vasocon- 
stiiction in response to hypoxia was stronger in 
100% plasma than in artificial perfusales composed 
of dextran or albumin, and they found that the 
presence of thrombocytes (platelets) in the perfusate 
led to a potentiation of the hypoxic response. Fur- 
thermore, repealing the hypoxic challenge with 
plasma as perfusate led to a noticeable increase in 
the size of the vasoconstriction in response to hy- 
poxia wiih each repetition. Kiviiy and Soutirada 
(107) suggest thai Ihe mechanism for the apparent 
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increase with repeated challenges may be due to Ihe 
lack of the protective adenosine which is initially 
released to vasodilatc. Tn light of Ihe fact that ATP 
has been shown to be released from erythrocytes by 
episodes of hypoxia (105). and that lumenderived 
ATP vasodilated the pulmonary vascular bed by 
evoking nitric oxide release (33), ihe role of the 
crythrocyle derived ATP as a protector agent during 
hypoxia can not be excluded. The function of tlirom- 
bocyte derived ATP is even less clear. 
•       Mast cell derived asoactive ATP 
Mast cells are plentiful in the walls and lumen of the 
airways, and pcriaitcrial mast cells (5,6,108) consti- 
tute another source of ATP with a potential vascular 
role (Fig. 3). The P^ purinoceptor is activated by 
ATP- (10.12.18) and mediates degranulation of 
inast cells (17,109-112") as well as the inhibition of 
ihe activity of natural killer ceils and macrophages 
(113.114). It has been shown that in response to 
acute hypoxia lung mast cells degranulate (6,11 ri- 
ll 7) releasing substances which can increase plasma 
extravasation as during inllammaiion, and it is re- 
ported that mast cell number increases in response to 
conditions of chronic hypoxia(6.1 18). Some studies 
have found a lack of correlation between mast cell 
concentration in the lungs of various species and the 
vigor of the pulmonary prcssor response to hypoxia 
(5,6). The question of whether changes in mast cell 
number in animals exposed to chronic condition of 
hypoxia is (he cause or the result of hypertension is 
still an open question, and the role of ATP in relation 
to mast cells is understood even less. 
CONCLUSION 
• Recognition of purinergic vasomechanisms 
have opened significant new avenues to our under- 
standing of how pulmonary vascular tone is main- 
tained and regulated. The finding of a novel P, 
purinoceptor evoked vasoconsiriction puts ATP back 
into contention as a mediator of hypoxic pulmonary 
vasoconstriction. and although appreciation of this 
non-adrenergic and non-cholinergic system is rela- 
tively recent, the studies show promise that drugs 
targeted to purinergic vasomechanisms will  have 
therapeutic use in pulmonary vascular medicine 
(119,120). 
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